RXi Pharmaceuticals Announces Upcoming Presentations at Leading Partnering and Scientific Conferences

MARLBOROUGH, Mass., April 27, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology, today announced several oral and poster presentations at leading partnering and scientific conferences on May 4, 6, 7 and 9, 2015.

Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO 

BioNetwork Partnering Summit

On Monday, May 4, 2015 from 12:05 to 12:20 p.m. EDT, Dr. Geert Cauwenbergh, Dr. Med. Sc., RXi's President and CEO, will present a corporate overview, including multiple business development opportunities available based on RXi's proprietary sd-rxRNA^® platform and extensive intellectual property portfolio.  The presentation will be available on the Company's website at www.rxipharma.com approximately one hour after the presentation.

Now in its 12^th year, the BioNetwork Partnering Summit has been providing a platform for business development executives across the pharmaceutical and biotechnology space to come together in an intimate setting and develop relationships that may lead to strategic partnerships. This conference is being held May 4-6, 2015 at the Trump International Beach Resort Miami, Sunny Isles Beach, FL.

Association for Research in Vision and Ophthalmology (ARVO) 2015 Annual Meeting

On Wednesday, May 6, 2015 in the 8:30 to 10:15 a.m. MDT poster session, data from an ongoing research collaboration between RXi Pharmaceuticals and Jade Therapeutics, on work in the area of corneal drug delivery to reduce scar formation, will be presented. These data may be viewed on Poster 4143-C0026 entitled, "Formulation and Release of sd‑rxRNA^® from a Cross-linked, Thiolated CMHA-based Film for Topical Delivery to Reduce the Formation of Corneal Scarring," presented during session 416.

On Thursday, May 7, 2015 in the 8:30 to 10:15 a.m. MDT poster session, data will be presented from a research collaboration, in the area of retinoblastoma, between RXi Pharmaceuticals and David Cobrinik, M.D., Ph.D., Principal Investigator at The Saban Research Institute of Children's Hospital Los Angeles. These data may be viewed on Poster 5473-B0032 entitled, "MDM2 Targeting sd‑rxRNA^® for Retinoblastoma Therapy," presented during session 509.

Both posters will be available on the Company's website at www.rxipharma.com approximately one hour after each presentation.

The Annual Meeting of ARVO is the largest gathering of eye and vision researchers in the world, attracting over 11,000 attendees from more than 75 countries.  ARVO is being held May 3-7, 2015 at the Colorado Convention Center, Denver, Colorado.

IBCs 17^th Annual TIDES: Oligonucleotide and Peptide Therapeutics from Research through Commercialization 

On Wednesday, May 6, 2015 at 11:45 a.m. PDT, Karen Bulock, Ph.D., RXi's Vice President of Research, will present an overview of the Company's dermal clinical program with RXI-109. The oral presentation entitled, "Clinical Development of RXI-109 to Prevent Dermal Scarring," will take place during the Clinical Updates on Oligonucleotides session.  Dr. Bulock's presentation will be available on the Company's website at www.rxipharma.com approximately one hour after the presentation.

The TIDES Summit is prominently known as the premier meeting place for CMC, clinical and discovery scientists to accelerate product development. This meeting is being held May 3-6, 2015 at the Town and Country Resort, San Diego, CA.

Society for Investigative Dermatology (SID) 74^th Annual Meeting

On Saturday, May 9, 2015, in the 10:00 a.m. to 12:00 p.m. EDT poster session, data will be presented on the Company's ongoing work with our sd-rxRNA^® compounds that target Collagenase (MMP1), a key enzyme involved in the breakdown of the extracellular matrix. MMP1-targeting compounds may potentially be beneficial in a number of therapeutic areas including skin aging disorders, arthritis, acne scarring and possibly cancer metastasis.  These data may be viewed on Poster 487 entitled, "Self-delivering RNAi Compounds Targeting Collagenase," during the Growth Factors, Cell Adhesion and Matrix Biology session.

On Saturday, May 9, 2015, in the 10:00 a.m. to 12:00 p.m. EDT poster session, data will be presented on the Company's ongoing work with our sd-rxRNA^® compounds that target Tyrosinase (TYR), a key enzyme in the synthesis of melanin. TYR-targeting compounds may be therapeutically useful in a number of areas including cutaneous hyperpigmentation disorders such as age spots, liver spots, freckles and potentially melanoma. These data may be viewed on Poster 642 entitled, "Tyrosinase Targeting Self-delivering RNAi Compounds," during the Pigmentation and Melanoma session.

Both posters will be available on the Company's website at www.rxipharma.com approximately one hour after each presentation.

The SID mission is to advance and promote the sciences relevant to skin health and disease through education, advocacy and scholarly exchange of scientific information. This annual meeting is being held May 6-9, 2015 at the Hilton Atlanta, Atlanta, GA.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a biotechnology company focused on discovering and developing innovative therapeutics primarily in the area of dermatology and ophthalmology that address high-unmet medical needs. Our discovery and clinical development programs are based on siRNA technology as well as immunotherapy agents. These compounds include, but are not limited to, our proprietary, self-delivering RNAi (sd-rxRNA^®) compounds for the treatment of dermal and retinal scarring. It also includes an immunomodulator, Samcyprone™, a proprietary topical formulation of diphenylcyclopropenone (DPCP), for the treatment of such disorders as alopecia areata, warts, and cutaneous metastases of melanoma. 

RXi's robust pipeline, coupled with an extensive patent portfolio, provides for product and business development opportunities across a broad spectrum. We are committed to being a partner of choice for academia, small companies, and large multinationals. We welcome ideas and proposals for strategic alliances, including in- and out-licensing opportunities, to advance and further develop strategic areas of interest. Additional information may be found on the Company's website, www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about future expectations and planned and future development of our product candidates, technologies and partnerships.  Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors."  Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.

Contact

RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
[email protected]

SOURCE RXi Pharmaceuticals Corporation

Related Links

http://www.rxipharma.com